<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03833479</url>
  </required_header>
  <id_info>
    <org_study_id>GEICO 78-C (ATOMICC)</org_study_id>
    <secondary_id>2018-002155-15</secondary_id>
    <nct_id>NCT03833479</nct_id>
  </id_info>
  <brief_title>TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation (ATOMICC)</brief_title>
  <acronym>ATOMICC</acronym>
  <official_title>A Randomized, Open Label, Phase II Trial of Anti-PD1, TSR-042, as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Investigación en Cáncer de Ovario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Investigación en Cáncer de Ovario</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with locally advanced cervical cancer (LACC) despite definitive chemo-radiotherapy,
      has a poor progression-free survival (PFS) and overall survival (OS). The hypothesis is that
      the use of TSR-042, checkpoint inhibitor, as consolidation therapy following concurrent
      chemo-radiation would increase PFS in these patients. The incorporation of immunotherapy
      after chemo-radiation is one the best scenarios for this approach, since takes advantages of
      &quot;the ideal microenvironment&quot; created after radiation. In a similar rationale, the phase 3
      study that compared the anti-programmed death ligand 1 antibody durvalumab as consolidation
      therapy with placebo in patients with stage III NSCLC who did not have disease progression
      after two or more cycles of platinum-based chemoradiotherapy, showed that progression-free
      survival was significantly longer with durvalumab than with placebo in all sub-groups
      regardless of response obtained to chemotherapy, namely patients with stable disease (SD)
      gained the same benefit that patients with partial response (PR). Due to the aforementioned
      biology of cervical cancer, the proven activity of anti programmed cell death protein 1
      (Anti-PD1) agents in metastatic and/or recurrent cervical cancer and the poor PFS and OS in
      patients with LACC despite definitive chemo-radiotherapy, we consider to analyze the Anti-PD1
      agent, TSR-042 as maintenance therapy after concurrent chemo-radiation (CCRT)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>30 months</time_frame>
    <description>Time from the date of randomization to the date of first documentation of disease progression or death due to any cause, whichever occurs first based on investigator assessment using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events (AEs)</measure>
    <time_frame>30 months</time_frame>
    <description>Incidence, nature and severity of adverse events (AEs) assessed by CTCAE version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>30 months</time_frame>
    <description>Time from the date of randomization to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes (PROs) of health-related quality of life (HRQOL)</measure>
    <time_frame>30 months</time_frame>
    <description>Mean changes from baseline score assessed by the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes (PROs) of health-related quality of life (HRQOL)</measure>
    <time_frame>30 months</time_frame>
    <description>Mean changes from baseline score assessed by EQ -5D-5L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes (PROs) of fatigue</measure>
    <time_frame>30 months</time_frame>
    <description>Mean changes from baseline score assessed by the PROMIS-Cancer-Fatigue Short Form 4a.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes (PROs) of pain</measure>
    <time_frame>30 months</time_frame>
    <description>Mean changes from baseline score assessed by a single item of the Brief Pain Inventory (BPI).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>No further treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No further treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TSR-042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TSR-042 treatment administered using a 30 -minute IV infusion (with a -5 minute and +15 minute window permitted).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Further Treatment</intervention_name>
    <description>No further treatment</description>
    <arm_group_label>No further treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSR-042</intervention_name>
    <description>Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months</description>
    <arm_group_label>TSR-042</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent before any study-specific procedure

          2. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
             of ≤ 1

          3. Participant must be a female ≥ 18 years of age

          4. Life expectancy ≥3 months

          5. Participant must have biopsy-confirmed squamous cell carcinoma, adenocarcinoma, or
             adenosquamous carcinoma of the cervix.

          6. Patients must have archival tumor tissue available that is formalin-fixed and paraffin
             embedded.

          7. At diagnosis:

               -  Federation of Gynecologists and Obstetricians (FIGO) stages IB2, IIA2, IIB with
                  pelvic lymph node involvement: Biopsy-proven pelvic node involvement, 2 or more
                  positive nodes by magnetic resonance imaging (MRI) or computed tomography (CT)
                  (≥1.5 cm shortest dimension), 2 or more positive nodes by Positron Emission
                  Tomography (PET) (with standardized uptake values (SUV) ≥2.5)

               -  FIGO stages IIIA, IIIB, IVA

               -  Any FIGO stage with para-aortic lymph node involvement: Biopsy-proven para-aortic
                  node involvement, 1 or more positive nodes by MRI or CT (≥1.5 cm shortest
                  dimension), 1 or more positive pelvic nodes by PET (with SUV ≥ 2.5)

          8. Subjects must have received combination chemotherapy and radiotherapy (CCRT) with
             curative intent. Patients must have received at least 4 doses of weekly cisplatin.

          9. Patients must have completed definitive treatment, namely chemo-radiation, up to 12
             weeks prior to sign the Informed Consent form.

         10. Toxicities resulting from chemo-radiation must resolve to ≤ Grade 1 prior to
             randomization.

         11. Participant must have adequate organ function, defined as follows:

               -  Absolute neutrophil count ≥ 1,500/µL

               -  Platelets ≥ 100,000/µL

               -  Hemoglobin ≥ 9 g/dL

               -  Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine
                  clearance ≥ 50 mL/min using Cockcroft-Gault equation for patients with creatinine
                  levels &gt; 1.5× institutional ULN

               -  Total bilirubin ≤ 1.5× ULN OR direct bilirubin ≤ 1× ULN

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN
                  unless liver metastases are present, in which case they must be ≤ 5× ULN

               -  International normalized ratio (INR) or prothrombin time (PT) ≤1.5× ULN unless
                  patient is receiving anticoagulant therapy as long as PT or partial
                  thromboplastin (PTT) is within therapeutic range of intended use of
                  anticoagulants. Activated partial thromboplastin time (aPTT) ≤1.5× ULN unless
                  patient is receiving anticoagulant therapy as long as PT or PTT is within
                  therapeutic range of intended use of anticoagulants

         12. Participant must agree to not donate blood during the study or for 90 days after the
             last dose of study treatment.

         13. Negative Test Results for Hepatitis

         14. Female participant has a negative serum pregnancy test within 72 hours prior to taking
             study treatment if of childbearing potential and agrees to abstain from activities
             that could result in pregnancy from screening through 150 days after the last dose of
             study treatment, or is of nonchildbearing potential.

         15. Participant must agree to not breastfeed during the study or for 150 days after the
             last dose of study treatment.

         16. Male partners must agree to use an adequate method of contraception starting with the
             first dose of study treatment through 150 days after the last dose of study treatment.

         17. Participant must be able to understand the study procedures and agree to participate
             in the study by providing written informed consent

        Exclusion Criteria:

          1. Histological types other than in inclusion criteria, like sarcomas, small cell
             carcinoma with neuroendocrine differentiation, non-epithelial cancers.

          2. FIGO Stage IVB (cancer has spread distantly).

          3. Subjects who have undergone a previous hysterectomy defined as removal of the entire
             uterus or will have a hysterectomy as part of their initial cervical cancer therapy.

          4. Has not achieved at least a partial response by Response Evaluation Criteria in Solid
             Tumors (RECIST) v1.1 after completion of CCRT administered with curative intent.

          5. Patients previously treated with chemotherapy except when used concurrently with
             radiation therapy. Patients who have received either concurrent paclitaxel with
             radiation therapy or carboplatin/paclitaxel as adjuvant therapy are ineligible for the
             study.

          6. Prior treatment with any anti-vascular endothelial growth factor (anti-VEGF) drug,
             including bevacizumab, CD137 agonists or immune checkpoint blockade therapies,
             anti-PD1, or anti-PDL1 therapeutic antibodies or anti-CTLA 4.

          7. Patients with a concomitant malignancy other than non-melanoma skin cancer.

          8. History of autoimmune disease

          9. History of idiopathic pulmonary fibrosis, organizing pneumonia , drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan.

         10. History of interstitial lung disease.

         11. Active tuberculosis.

         12. Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1.

         13. Administration of a live, attenuated vaccine within 14 days before Cycle 1, Day 1 or
             anticipation that such a live attenuated vaccine will be required during the study
             Influenza vaccination should be given during influenza season only. Patients must not
             receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to
             Cycle 1, Day 1 or at any time during the study.

         14. Treatment with systemic immunostimulatory agents within 6 weeks or 5 half-lives of the
             drug, whichever is shorter, prior to Cycle 1, Day 1.

         15. Treatment with systemic immunosuppressive medications within 2 weeks prior to Cycle 1,
             Day 1.

         16. Women that are breastfeeding or pregnant.

         17. Demonstration of any other disease, neurological or metabolic dysfunction, found upon
             physical examination or laboratory tests involving a reasonable suspicion of the
             existence of a disease or condition that contraindicates the use of an experimental
             drug, or that involves an increased risk to the patient of treatment-related
             complications.

         18. No medical or psychiatric illness that may impede the performance of a systemic or
             surgical treatment

         19. Participant must not be simultaneously enrolled in any interventional clinical trial

         20. Participant must not have had major surgery ≤ 3 weeks prior to initiating protocol
             therapy and participant must have recovered from any surgical effects.

         21. Participant must not have received investigational therapy ≤ 4 weeks, or within a time
             interval less than at least 5 half-lives of the investigational agent, whichever is
             shorter, prior initiating protocol therapy.

         22. Participant has had radiation therapy encompassing &gt;20% of the bone marrow within 2
             weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy.

         23. Participant must not have a known hypersensitivity to TSR-042 components or
             excipients.

         24. Participant must not have a serious, uncontrolled medical disorder or nonmalignant
             systemic disease. Examples include, but are not limited to, uncontrolled ventricular
             arrhythmia, recent (within 90 days) myocardial infarction, chronic obstructive
             pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord
             compression, superior vena cava syndrome, or any psychiatric disorder that prohibits
             obtaining informed consent

         25. Participant must not have known, symptomatic brain or leptomeningeal metastases

         26. Patient experienced ≥ Grade 3 immune-related adverse events (AE) with prior
             immunotherapy, with the exception of non-clinically significant lab abnormalities.

         27. Participant has a known history of human immunodeficiency virus (type 1 or 2
             antibodies).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Oaknin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlota de Blas</last_name>
    <phone>+34910097258</phone>
    <email>cblas@grupogeico.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana B Sanchez</last_name>
    </contact>
    <investigator>
      <last_name>Ana B Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Santaballa</last_name>
    </contact>
    <investigator>
      <last_name>Ana Santaballa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia- Donostia Unibertsitate Ospitalea</name>
      <address>
        <city>Donostia</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Churruca, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cristina Churruca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isaura Fernández Pérez</last_name>
    </contact>
    <investigator>
      <last_name>Isaura Fernández Pérez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Oaknin</last_name>
    </contact>
    <investigator>
      <last_name>Ana Oaknin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Gaba</last_name>
    </contact>
    <investigator>
      <last_name>Lydia Gaba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H Reina Sofía Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jesus Rubio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Jesus Rubio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Barretina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pilar Barretina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet</name>
      <address>
        <city>Hospitalet del Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Pardo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Beatriz Pardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Redondo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrés Redondo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Gonzalez, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio González, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Marquina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gloria Marquina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Guerra, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eva Guerra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Manso Sánchez, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Luis Manso Sánchez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerónimo Martínez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jerónimo Martínez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Garcia Martinez</last_name>
    </contact>
    <investigator>
      <last_name>Elena García Martínez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose Bermejo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria José Bermejo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Alarcón</last_name>
    </contact>
    <investigator>
      <last_name>Jesús Alarcón, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Iglesias González, MD</last_name>
    </contact>
    <investigator>
      <last_name>María Iglesias González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda García</last_name>
    </contact>
    <investigator>
      <last_name>Yolanda García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana De Juán Ferre</last_name>
    </contact>
    <investigator>
      <last_name>Ana de Juán Ferre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Purificación Estévez García, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Purificación Estévez García, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angels Arcusa Lanza</last_name>
    </contact>
    <investigator>
      <last_name>Angels Arcusa Lanza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Romero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ignacio Romero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José A Pérez Fidalgo, MD</last_name>
    </contact>
    <investigator>
      <last_name>José A Pérez Fidalgo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TSR-042</keyword>
  <keyword>Anti-PD1</keyword>
  <keyword>advanced cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

